Loading clinical trials...
Loading clinical trials...
Post-marketing Surveillance Study for Verquvo (Vericiguat) in Korean Heart Failure Patients With Reduced Ejection Fraction
Conditions
Interventions
Vericiguat (Verquvo, BAY1021189)
Locations
1
South Korea
Many Locations
Multiple Locations, South Korea
Start Date
November 30, 2023
Primary Completion Date
August 31, 2027
Completion Date
October 31, 2027
Last Updated
April 17, 2026
NCT06632483
NCT05093933
NCT06697353
NCT05974189
NCT06363110
NCT02768298
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions